A major new study reveals that older adults with cancer and type 2 diabetes who take GLP-1 receptor agonist medications (GLP-1RAs) experience significantly better overall survival rates compared ...

Postmarketing safety profile of chimeric antigen receptor (CAR) T cell therapies in diffuse large B-cell lymphoma (DLBCL): Analysis of real-world (RW) AE reporting from the FDA Adverse Event Reporting ...

The Derek Carr-less Saints might be moving toward an awkward quarterback decision between a loyal son of their city and a loyal son of one of their coaches.

Bristol Myers Squibb’s Cobenfy failed to outdistance a placebo in a Phase 3 test that evaluated the drug as an adjunct to antipsychotics in schizophrenia patients. Last September, the FDA ...

Fee R et al. Reasons for Switching Oral Antipsychotic Medications and Related Patterns of Care and Costs in Patients With Schizophrenia Initiating Monotherapy Treatment: Claims-Linked Chart Study.

Use of Aripiprazole in the Treatment of Schizophrenia: Consensus Report The advantageous benefit/risk profile of atypical antipsychotic agents over conventional agents is reflected in ...

The use of interleukin-2 (IL-2)-directed therapies has been associated with systemic toxicities, regulatory T cell (Treg) activation and limited efficacy so far. Researchers from Regeneron ...

Bristol Myers Squibb’s Cobenfy treats schizophrenia by going after a different target than currently available antipsychotic drugs, which is intended to offer better efficacy and safety. The ...

Bristol-Myers Squibb (BMY) stock rises as FDA approves Cobenfy as a ovel treatment for adults with the psychiatric disorder schizophrenia. Read more here.

The Food and Drug Administration (FDA) approved Bristol Myers Squibb’s schizophrenia drug Cobenfy Thursday — the first new approved drug for the disease in some 30 years. The drug, a combination of ...

Unlike previous antipsychotics, which target dopamine receptors in the brain, Cobenfy homes in on cholinergic receptors, the FDA said in its statement.